All In Biotech

NDA 209482 · Glaxosmithkline

Trelegy Ellipta

Fluticasone Furoate, Umeclidinium Bromide, Vilanterol Trifenatate · Inhalation

Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Sep 18, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

737

240 Phase 3, 19 recruiting

FAERS reports

43,081

17,505 serious, 3,373 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2023.

TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 18 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 ) 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease TRELEGY ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). 1.2 Maintenance Treatment of Asthma TRELEGY ELLIPTA is indicated for the maintenance treatment of asthma in patients aged 18 years and older. 1.3 Limitations of Use TRELEGY ELLIPTA is NOT indicated for the relief of acute bronchospasm.

Mechanism: TRELEGY ELLIPTA TRELEGY ELLIPTA contains fluticasone furoate, umeclidinium, and vilanterol. The mechanisms of action described below for the individual components apply to TRELEGY ELLIPTA. These drugs represent 3 different classes of medications (an ICS, an anticholinergic, and a LABA), each having different effects on clinical and physiological indices. Fluticasone Furoate Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TRELEGY ELLIPTA · FLUTICASONE FUROATE 0.1MG/INH; UMECLIDINIUM BROMIDE EQ 0.0625MG BASE/INH; VILANTEROL TRIFENATATE EQ 0.025MG BASE/INH · POWDER, INHALATION · Prescription
  • TRELEGY ELLIPTA · FLUTICASONE FUROATE 0.2MG/INH; UMECLIDINIUM BROMIDE EQ 0.0625MG BASE/INH; VILANTEROL TRIFENATATE EQ 0.025MG BASE/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Furoate" as an intervention, any sponsor and status, largest first.

All 737 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea6,025
  • drug ineffective3,674
  • product dose omission issue3,485
  • wrong technique in device usage process3,401
  • product complaint3,063
  • cough3,012
  • death2,401
  • pneumonia2,203
  • asthma1,886
  • chronic obstructive pulmonary disease1,648
  • fatigue1,468
  • off label use1,436

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20166
201721
20181,227
20193,883
20203,782
20214,331
20224,768
20235,640
20246,970
20257,120
20265,332

Recalls

2 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter)

2024 spending

$5.29B

Beneficiaries

1,268,914

6,250,872 claims

Per beneficiary

$4,172

$10.52 per unit

View as table
YearSpending
2020$1,487,802,308
2021$2,393,151,303
2022$3,340,110,326
2023$4,455,884,010
2024$5,294,401,777

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 243 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.